ACUTE MYELOID LEUKEMIA; AML, MYELODYSPLASTIC SYNDROME; MDS
Conditions
Keywords
ACUTE MYELOID LEUKEMIA, AML, MDS, MYELODYSPLASTIC SYNDROME
Brief summary
This is a Phase 1a/b study to evaluate the safety and tolerability of an antibody conditioning regimen known as JSP191, in combination with low dose radiation and fludarabine, in subjects with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) undergoing allogenic blood stem cell transplantation.
Detailed description
This is a Phase 1a/b study to evaluate the safety and tolerability of an antibody conditioning regimen known as JSP191, in combination with low dose radiation and fludarabine in subjects with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) undergoing allogenic blood stem cell transplantation. Blood Stem Cell transplantation offers the only potentially curative therapy for many forms of Acute Myeloid Leukemia (AML) and for Myelodysplastic Syndrome (MDS). While standard of care conditioning regimens given prior to blood Stem Cell transplantation, such as standard TBI/Flu conditioning are well tolerated, they are associated with increased rates of relapse due to persistence of disease causing Hematopoietic Stem Cells and insufficient graft versus leukemia effect. The biological conditioning regimen JSP191 is an antibody that binds to CD117. CD117 is the receptor for Stem Cell Factor on blood forming cells. CD117 binding to Stem Cell Factor is critical for survival and maintenance of blood forming stem cells. The binding of JSP191 to CD117 blocks CD117 from binding to Stem Cell Factor on blood forming stem cells. In the absence of CD117/Stem Cell Factor binding, hematopoietic stem cells that are currently occupying the bone marrow niches in MDS/AML patients are depleted. This study will investigate the safety and tolerability of adding JSP191 (an anti-CD117 monoclonal antibody therapy) to standard TBI/Flu conditioning regimen in adults with AML and MDS undergoing hematopoietic stem cell transplant.
Interventions
Procedure: single intravenous infusion of JSP191 antibody
Sponsors
Jasper Therapeutics, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: * AML/MDS as defined by specific criteria, including but not limited to the following subtypes: 1. AML in CR 2. MDS \< 5% BM blasts 3. MDS 5 - 10% BM blasts 4. AML not in CR or MDS \> 10% BM blasts * Patients with human leukocyte antigen (HLA) matched related or unrelated donors * Adequate end organ function as defined in study protocol Key
Exclusion criteria
* Patients with any acute or uncontrolled infections * Patients receiving any other investigational agents * Patients with active non-hematologic malignancy * Prior allogeneic hematologic cell transplantation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The number of subjects experiencing adverse events and serious adverse events will be assessed. | Up to 1 year post Donor Cell Transplant (28 days dose limiting toxicity period) | The number of subjects experiencing adverse events and serious adverse events will be assessed. |
| The number of dose limiting toxicities will be assessed. | Up to 1 year post Donor Cell Transplant (28 days dose limiting toxicity period) | The number of dose limiting toxicities will be assessed. |
| The type of dose limiting toxicities will be assessed. | Up to 1 year post Donor Cell Transplant (28 days dose limiting toxicity period) | The type of dose limiting toxicities will be assessed. |
Countries
United States
Contacts
Primary ContactClinical Trials, Jasper Therapeutics, Inc.
Outcome results
None listed